Polymed - Public Comps and Valuation Multiples

Polymed Overview

About Polymed

Poly Medicure Ltd engages in the manufacturing and sale of medical devices. It offers disposable medical devices for infusion therapy, blood management, gastroenterology, vascular access, surgery and wound drainage, anesthesia, and urology. Some of its products include Ventilator Circuit Combo Kits, Bain Circuits, Safety Introducer Needles, High-Pressure Vaccum Bottle-Triplet, Catheters, and others. Geographically, it derives a majority of its revenue from exports. The company operates under one segment namely Medical Devices.

Founded

1995

HQ

Employees

3.1K+

Website

polymedicure.com

Sectors

Medical Supplies

Financials

LTM Revenue $205M

LTM EBITDA $54.7M

EV

$2.0B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Polymed Financials

As of November 2025, Polymed reported last 12-month revenue of $205M and EBITDA of $54.7M.

In the same period, Polymed generated $137M in LTM gross profit and $40.5M in net income.

See Polymed valuation multiples based on analyst estimates

Polymed P&L

In the most recent fiscal year, Polymed reported revenue of $184M and EBITDA of $60.8M.

Polymed expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Polymed valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$205M	XXX	$184M	XXX	XXX	XXX
Gross Profit	$137M	XXX	$105M	XXX	XXX	XXX
Gross Margin	67%	XXX	57%	XXX	XXX	XXX
EBITDA	$54.7M	XXX	$60.8M	XXX	XXX	XXX
EBITDA Margin	27%	XXX	33%	XXX	XXX	XXX
EBIT	$45.7M	XXX	$42.3M	XXX	XXX	XXX
EBIT Margin	22%	XXX	23%	XXX	XXX	XXX
Net Profit	$40.5M	XXX	$37.6M	XXX	XXX	XXX
Net Margin	20%	XXX	20%	XXX	XXX	XXX
Net Debt	XXX	XXX	$18.8M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Polymed including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $205M. EBITDA for the last twelve months was $54.7M. In the most recent fiscal year, Polymed achieved $184M in revenue and $60.8M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$205M	Analyst estimates available to subscribers	$184M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$137M	Analyst estimates available to subscribers	$105M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	67.2% gross margin	Analyst estimates available to subscribers	57.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$54.7M	Analyst estimates available to subscribers	$60.8M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	26.8% EBITDA margin	Analyst estimates available to subscribers	33.1% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$45.7M	Analyst estimates available to subscribers	$42.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	22.3% EBIT margin	Analyst estimates available to subscribers	23.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$40.5M	Analyst estimates available to subscribers	$37.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	19.8% net profit margin	Analyst estimates available to subscribers	20.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$18.8M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Polymed

This financial data table provides comprehensive performance metrics for Polymed, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Polymed generated $205M in revenue over the last twelve months.
The company achieved $54.7M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $137M.
Net income over the last twelve months reached $40.5M.

Fiscal Year Performance

In the most recent fiscal year, Polymed reported $184M in total revenue.
Fiscal year EBITDA was $60.8M.
The company maintained a gross profit margin of 57.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.1%.
Net profit margin reached 20.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Polymed. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Polymed Stock Performance

Polymed has current market cap of INR 191B (or $2.1B), and EV of INR 183B (or $2.0B).

Market Cap Evolution

Polymed Stock Data

As of December 12, 2025, Polymed's stock price is INR 1886 (or $21).

See Polymed trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.0B	$2.1B	XXX	XXX	XXX	XXX	$0.42

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Polymed Valuation Multiples

Polymed's trades at 11.5x EV/Revenue multiple, and 35.4x EV/EBITDA.

See valuation multiples for Polymed and 15K+ public comps

Polymed Financial Valuation Multiples

As of December 12, 2025, Polymed has market cap of $2.1B and EV of $2.0B.

Equity research analysts estimate Polymed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Polymed has a P/E ratio of 52.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV (current)	$2.0B	XXX	$2.0B	XXX	XXX	XXX
EV/Revenue	9.9x	XXX	11.5x	XXX	XXX	XXX
EV/EBITDA	37.1x	XXX	35.4x	XXX	XXX	XXX
EV/EBIT	44.4x	XXX	50.6x	XXX	XXX	XXX
EV/Gross Profit	14.8x	XXX	n/a	XXX	XXX	XXX
P/E	52.4x	XXX	60.0x	XXX	XXX	XXX
EV/FCF	-398.6x	XXX	-258.2x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Polymed Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Polymed Margins & Growth Rates

Polymed's last 12 month revenue growth is 20%

Polymed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $21K for the same period.

Polymed's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Polymed's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Polymed and other 15K+ public comps

Polymed Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	20%	XXX	19%	XXX	XXX	XXX
EBITDA Margin	27%	XXX	33%	XXX	XXX	XXX
EBITDA Growth	21%	XXX	8%	XXX	XXX	XXX
Rule of 40	53%	XXX	53%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	77%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$21K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	3%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	34%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial